Literature DB >> 30484262

Patterns of Regression in Breast Cancer after Primary Systemic Treatment.

Tamás Zombori1, Gábor Cserni2,3.   

Abstract

Despite national guidelines, the evaluation of effects of primary systemic treatment (PST) in breast cancer is a complex challenge. Our aims were to evaluate the response patterns focusing on correlations of radiological and pathological tumor size, regression heterogeneity in different molecular subtypes, cellularity changes and the incidence of enlarged, multinucleated neoplastic cells related to therapy. Slides of pretreatment biopsies and resection specimens of consecutive cases were reevaluated focusing on heterogeneity of regression per whole slide, and 40x or 100x magnification fields. Alteration in cellularity and the presence of multinucleated tumor giant cells were noted. The correlation of pathological and radiological sizes and their alterations were analyzed by Spearman rank correlation. The present study included 106 tumors. A decrease in size (84.9%) and cellularity (76.4%) was noted in all molecular subtypes. Inhomogeneous regression was found in 45.3%, with minor inhomogeneity in the majority. Scatter pattern regression was seen only in 8 cases (7.5%). Significant correlations were found between the pathological and radiological sizes (p = 0.02), and between the alterations of cellularity and pathological and radiological size (p = 0.04; p = 0.03, respectively). Multinucleated tumor giant cells were noted in 17.9% (n = 19), nearly exclusively in cases treated with PST including taxanes. Regression inhomogeneity following PST is present in about half of the cases, and is not related to molecular subtypes. The evaluation of the maximum area of the tumor bed is recommended for the proper evaluation of regression. Multinucleated tumor giant cells are related to PST including taxane derivate, and may cause upgrading.

Entities:  

Keywords:  Breast cancer; Molecular subtypes; Primary systemic therapy; Regression pattern

Mesh:

Substances:

Year:  2018        PMID: 30484262     DOI: 10.1007/s12253-018-0557-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  29 in total

Review 1.  International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations.

Authors:  Manfred Kaufmann; Gunter von Minckwitz; Roy Smith; Vicente Valero; Luca Gianni; Wolfgang Eiermann; Anthony Howell; Serban Dan Costa; Philippe Beuzeboc; Michael Untch; Jens-Uwe Blohmer; Hans-Peter Sinn; Rolf Sittek; Rainer Souchon; Augustinos H Tulusan; Tanja Volm; Hans-Jörg Senn
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

2.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

Authors:  Manfred Kaufmann; Gabriel N Hortobagyi; Aron Goldhirsch; Suzy Scholl; Andreas Makris; Pinuccia Valagussa; Jens-Uwe Blohmer; Wolfgang Eiermann; Raimund Jackesz; Walter Jonat; Annette Lebeau; Sibylle Loibl; William Miller; Sigfried Seeber; Vladimir Semiglazov; Roy Smith; Rainer Souchon; Vered Stearns; Michael Untch; Gunter von Minckwitz
Journal:  J Clin Oncol       Date:  2006-04-20       Impact factor: 44.544

3.  Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma.

Authors:  F E Sharkey; S L Addington; L J Fowler; C P Page; A B Cruz
Journal:  Mod Pathol       Date:  1996-09       Impact factor: 7.842

4.  Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease.

Authors:  Janice Diaz; Lesley Stead; Nella Shapiro; Rosanne Newell; Olivier Loudig; Yungtai Lo; Joseph Sparano; Susan Fineberg
Journal:  Breast Cancer Res Treat       Date:  2013-02-17       Impact factor: 4.872

5.  Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer.

Authors:  A H Honkoop; H M Pinedo; J S De Jong; H M Verheul; S C Linn; K Hoekman; J Wagstaff; P J van Diest
Journal:  Am J Clin Pathol       Date:  1997-02       Impact factor: 2.493

Review 6.  [Pathological diagnosis, work-up and reporting of breast cancer. Recommendations of the 3rd Hungarian Consensus Conference on Breast Cancer].

Authors:  Gábor Cserni; Janina Kulka; Monika Francz; Balázs Járay; Endre Kálmán; Ilona Kovács; Tibor Krenács; Nóra Udvarhelyi; László Vass
Journal:  Magy Onkol       Date:  2016-06-20

7.  American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.

Authors:  Lisa A Carey; Richard Metzger; E Claire Dees; Frances Collichio; Carolyn I Sartor; David W Ollila; Nancy Klauber-DeMore; Jan Halle; Lynda Sawyer; Dominic T Moore; Mark L Graham
Journal:  J Natl Cancer Inst       Date:  2005-08-03       Impact factor: 13.506

8.  [Preoperative chemotherapy in breast cancer and the development of new predictive markers].

Authors:  C Denkert; O Schickling; G von Minckwitz
Journal:  Verh Dtsch Ges Pathol       Date:  2006

9.  Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update.

Authors:  Sharon H Giordano; Sarah Temin; Sarat Chandarlapaty; Jennie R Crews; Francisco J Esteva; Jeffrey J Kirshner; Ian E Krop; Jennifer Levinson; Nancy U Lin; Shanu Modi; Debra A Patt; Jane Perlmutter; Naren Ramakrishna; Eric P Winer; Nancy E Davidson
Journal:  J Clin Oncol       Date:  2018-06-25       Impact factor: 44.544

10.  Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer.

Authors:  P Chollet; S Amat; H Cure; M de Latour; G Le Bouedec; M-A Mouret-Reynier; J-P Ferriere; J-L Achard; J Dauplat; F Penault-Llorca
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.